EVQLV
At EVQLV, we help biopharma companies that spend tens of millions of dollars and years of time on antibody discovery only to fail 75% of the time. Using our laboratory validated AI, we reduce the time of discovery to weeks and provide failure-resistant antibodies. At EVQLV, we accelerate the speed that healing reaches those in need.
EVQLV
Industry:
Artificial Intelligence Biotechnology Health Care Life Science Machine Learning Pharmaceutical
Founded:
2019-12-15
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.evqlv.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Current Employees Featured
Founder
Official Site Inspections
http://www.evqlv.com
- Host name: 199.60.103.168
- IP address: 199.60.103.168
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "EVQLV"
EVQLV - Crunchbase Company Profile & Funding
EVQLV leverages advances in computation to revolutionize the design and development of antibody-based therapeutics, diagnostics, and reagents. EVQLV provides AI-powered de novo …See details»
About Us - EVQLV
As the principal architect of EVQLV’s platform, his work produced 7 de novo binding antibodies several months after the founding of EVQLV. Brett’s machine learning expertise is focused on reinforcement learning applied to generative …See details»
EVQLV Company Profile 2025: Valuation, Funding & Investors
Jan 6, 2021 EVQLV General Information Description. Developer of antibody design platforms intended for the discovery and optimization of therapeutic antibodies. The company's platform …See details»
EVQLV - LinkedIn
EVQLV Biotechnology New York, NY 1,467 followers Leveraging advances in computation to revolutionize the design and development of therapeutic antibodiesSee details»
EVQLV - Company Profile - Tracxn
Jan 3, 2025 EVQLV - Developer of immunotherapies for cancer and immune diseases. Raised funding from 4 investors. Founded by Andrew Satz and Brett Averso in the year 2019. EVQLV …See details»
EVQLV, Inc. - IEEE Entrepreneurship
EVQLV, Inc. develops artificial intelligence, engineered with life science data and biological knowledge, to accelerate the speed at which biological therapies reach patients. The …See details»
EVQLV - Overview, News & Similar companies | ZoomInfo.com
Dec 18, 2023 Who is EVQLV. EVQLV develops artificial intelligence, engineered with life science data and biological knowledge, to accelerate the speed at which biologic thera pies …See details»
EVQLV - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Pre Seed Round - EVQLV . 1: …See details»
EVQLV INC Company Profile | Surfside, FL - Dun & Bradstreet
This information is updated and provided by EVQLV INC. The content available on the D&B Business Directory is provided "as-is" and "as-available" and may not be reviewed or validated …See details»
EVQLV - VentureRadar
Website: https://evqlv.com. Our Story Our founders, Brett and Andrew, met while studying data science at Columbia University. They had both watched loved ones suffer from illness, so they …See details»
TechTalk: Biotech Startup Evolving the Journey to Therapeutic …
Oct 8, 2024 Andrew Satz, Co-Founder and CEO of EVQLV, talks with EisnerAmper's TechTalk host Fritz Spencer about his startup’s mission to leverage advances in computation to …See details»
Stetson Hatter Angel Network Invests in AI – EVOLVE Magazine
Stetson University’s Hatter Angel Network, a group of accredited investors comprised of Stetson University alumni and faculty, recently invested $135,000 in EVQLV, a biotechnology company …See details»
EVQLV and Manhattan BioSolutions Enter into Strategic …
New York, NY August 25, 2020—EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a strategic research collaboration …See details»
EVQLV - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. EVQLV . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 43. Monthly Visits 76. …See details»
Accelerating Antibodies and Biologics to the Clinic - HHS.gov
EVQLV’s tech can develop rapid diagnostic tests to identify AMR pathogens and resistance proteins: Expedite diagnostic test development using antibodies Identify epitopes, optimize …See details»
Andrew Satz - EVQLV - LinkedIn
In the rapidly evolving intersection of technology and human health, I've built a niche… · Experience: EVQLV · Education: Columbia University in the City of New York · Location: …See details»
Our Technology - EVQLV
At EVQLV, we continuously expand our capabilities with in silico, de novo antibody discovery to transform the pace, cost, and scale of drug development. Our technology enhancements …See details»
EVQLV | VentureRadar
Website: https://evqlv.com. Our Story Our founders, Brett and Andrew, met while studying data science at Columbia University. They had both watched loved ones suffer from illness, so they …See details»
What is EVQLV? Company Culture, Mission, Values | Glassdoor
EVQLV. Is this your company? This employer has not claimed their Employer Profile and is missing out on connecting with our community. Connect with our community. Claim your Free …See details»